ReviewDrugs2012
New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function.
Review in Drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 86 citations in OpenAlex.
- Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant.Journal of thrombosis and thrombolysis · 2016Trial
- Warfarin use in hemodialysis patients with atrial fibrillation: decisions based on uncertainty.BMC nephrology · 2013Trial
- Article
- Apixaban Concentrations and Effects on Coagulation in Patients With Nephrotic Syndrome.Kidney medicine · 2025Article
- Anticoagulation in Chronic Kidney Disease.Drugs · 2024Review
- [Update on point-of-care-based coagulation treatment : Systems, reagents, device-specific treatment algorithms].Die Anaesthesiologie · 2024Review
- Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions.Frontiers in pharmacology · 2022Article
- Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.European stroke journal · 2019Article
- Post-transplant diabetes mellitus in patients with solid organ transplants.Nature reviews. Endocrinology · 2019Review
- Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy.Frontiers in oncology · 2019Article
- Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.Internal and emergency medicine · 2017Review
- Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment.Journal of thrombosis and thrombolysis · 2017Article
- Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies.Drug safety · 2016Review
- Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2016Review
- Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation.Critical care (London, England) · 2016Review
- Monitoring anticoagulant therapy with new oral agents.World journal of methodology · 2015Review
- Use Patterns and Unlabeled Uses of Target-Specific Oral Anticoagulants: A Single-Center Experience.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2015Article
- New Oral Anticoagulants: How Do We Use Them Wisely?Current cardiology reports · 2015Review
- Oral anticoagulants and risk of nephropathy.Drug safety · 2015Review
- Current state of anticoagulants to treat deep venous thrombosis.Current cardiology reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral anticoagulant therapy (OAT) is widely used to prevent and treat thromboembolic events. Traditionally, warfarin has been the drug of choice and, indeed, this drug is effective and provides a more than 60% reduction in stroke risk in patients with atrial fibrillation. However, OAT entails an increased bleeding risk, and management of this is challenging. Among other things, new oral anticoagulant drugs offer fixed dosing, more predictable pharmacokinetics and fewer interactions with drugs and food. Moreover, these drugs seem to provide an improved benefit-risk ratio with respect to thromboembolic events and bleeding complications in a broad patient population. The new drugs differ from traditional OAT with respect to their mechanism of action and pharmacokinetics, especially with respect to elimination through the kidneys. These drugs may potentially cause bleeding complications in patients with reduced drug excretion due to impaired renal function. Dabigatran etexilate and rivaroxaban carry the highest risk due to a high degree of renal excretion, whereas the risk for apixaban, edoxaban and betrixaban seems lower. Pharmacokinetic studies and data from clinical studies have provided information on how to guide dosing in patients with renal impairment. However, the risk of drug accumulation and bleeding may be amplified by several drug-drug interactions. This article provides a review of the literature on the pharmacology of new anticoagulant drugs with particular focus on the impact of impaired renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.